Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II studyXiangrui Meng, Feng Wang, Jianxiang Xing et al.|European Journal of Cancer|2024Cited by 18